(Q36726404)

15 August 2017

1 reference

title

Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping (English)

1 reference

15 August 2017

1 reference

Frank D

1

1 reference

15 August 2017

Jaehde U

series ordinal

2

1 reference

15 August 2017

Fuhr U

series ordinal

3

1 reference

15 August 2017

publication date

2 February 2007

1 reference

European Journal of Clinical Pharmacology

15 August 2017

published in

1 reference

15 August 2017

volume

63

1 reference

15 August 2017

issue

4

1 reference

15 August 2017

page(s)

321-333

1 reference

Sparteine oxidation polymorphism: a family study

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S00228-006-0250-8

The influence of enzyme induction on polymorphic sparteine oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00228-006-0250-8

Lack of pharmacokinetic interaction between nifedipine, sparteine and phenytoin in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00228-006-0250-8

Genetically determined oxidation capacity and the disposition of debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00228-006-0250-8

Defective N-oxidation of sparteine in man: A new pharmacogenetic defect

21 January 2018

1 reference

12 December 2020

LC-MS/MS analysis of dextromethorphan metabolism in human saliva and urine to determine CYP2D6 phenotype and individual variability in N-demethylation and glucuronidation.

1 reference

12 December 2020

A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin

1 reference

12 December 2020

Use of probe drugs as predictors of drug metabolism in humans

1 reference

12 December 2020

Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activity

1 reference

12 December 2020

The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes

1 reference

12 December 2020

Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension

1 reference

12 December 2020

Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities

1 reference

12 December 2020

CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans

1 reference

12 December 2020

Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design

1 reference

12 December 2020

4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine

1 reference

12 December 2020

Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates

1 reference

12 December 2020

Utility of a one-point (3-hour postdose) plasma metabolic ratio as a phenotyping test using metoprolol in two east Asian populations

1 reference

12 December 2020

Dextromethorphan O-demethylation and dextrorphan glucuronidation in a French population

1 reference

12 December 2020

Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda

1 reference

12 December 2020

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

1 reference

12 December 2020

Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes

1 reference

12 December 2020

Sparteine oxidation polymorphism: phenotyping by measurement of sparteine and its dehydrometabolites in plasma

1 reference

12 December 2020

Metoprolol metabolism via cytochrome P4502D6 in ethnic populations

1 reference

12 December 2020

Metoprolol alpha-hydroxylation is a poor probe for debrizoquine oxidation (CYP2D6) polymorphism in Jordanians

1 reference

12 December 2020

Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation

1 reference

12 December 2020

Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs

1 reference

12 December 2020

Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5 1 cocktail".

1 reference

12 December 2020

Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes

1 reference

12 December 2020

Codeine intoxication associated with ultrarapid CYP2D6 metabolism

1 reference

12 December 2020

Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes

1 reference

12 December 2020

Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences

1 reference

12 December 2020

Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping.

1 reference

12 December 2020

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

1 reference

12 December 2020

Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis

1 reference

12 December 2020

Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH.

1 reference

12 December 2020

Assessment of cytochrome P450 activity by a five-drug cocktail approach

1 reference

12 December 2020

Intra-individual variability and influence of urine collection period on dextromethorphan metabolic ratios in healthy subjects

1 reference

12 December 2020

An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19.

1 reference

12 December 2020

In-vivo indices of CYP2D6 activity: comparison of dextromethorphan metabolic ratios in 4-h urine and 3-h plasma

1 reference

12 December 2020

The urinary excretion of dextromethorphan and three metabolites in dogs and humans

1 reference

12 December 2020

Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over study

1 reference

12 December 2020

Phenotyping polymorphic drug metabolism in the French Caucasian population

1 reference

12 December 2020

Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI)

1 reference

12 December 2020

In-vivo indices of enzyme activity: the effect of renal impairment on the assessment of CYP2D6 activity

1 reference

12 December 2020

Influence of chronic renal failure on stereoselective metoprolol metabolism in hypertensive patients

1 reference

12 December 2020

Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation

1 reference

12 December 2020

Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine

1 reference

12 December 2020

Omission of the deconjugation step in urine analysis and the unaltered outcome of CYP2D6 phenotyping with dextromethorphan

1 reference

12 December 2020

Problems and perspectives of phenotyping for drug-metabolizing enzymes in man.

1 reference

12 December 2020

Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities?

1 reference

12 December 2020

Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers

1 reference

12 December 2020

Oxidation phenotype--a major determinant of metoprolol metabolism and response

1 reference

12 December 2020

Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity

1 reference

12 December 2020

Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study

1 reference

12 December 2020

Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.

1 reference

12 December 2020

Evaluation of dextromethorphan metabolism using hepatocytes from CYP2D6 poor and extensive metabolizers

1 reference

12 December 2020

Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers

1 reference

12 December 2020

Inhibitory effects of neuroleptics on debrisoquine oxidation in man

1 reference

12 December 2020

CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication.

1 reference

12 December 2020

Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A

1 reference

12 December 2020

The hypoalgesic effect of tramadol in relation to CYP2D6*

1 reference

12 December 2020

Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects

1 reference

12 December 2020

Pharmacokinetics of opioids in liver disease

1 reference

12 December 2020

Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers

1 reference

12 December 2020

Polymorphic hydroxylation of Debrisoquine in man.

1 reference

12 December 2020

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

1 reference

12 December 2020

Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs

1 reference

12 December 2020

Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians

1 reference

12 December 2020

Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance

1 reference

12 December 2020

Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms

1 reference

12 December 2020

Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes

1 reference

12 December 2020

Pharmacogenetics of dextromethorphan O-demethylation in man.

1 reference

12 December 2020

Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification

1 reference

12 December 2020

How useful is the "cocktail approach" for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?

1 reference

12 December 2020

Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach

1 reference

12 December 2020

The metabolism of tramadol by human liver microsomes

1 reference

12 December 2020

Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population

1 reference

12 December 2020

Salivary analysis for determination of dextromethorphan metabolic phenotype

1 reference

12 December 2020

Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6.

1 reference

12 December 2020

Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme

1 reference

12 December 2020

Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase

1 reference

12 December 2020

Inhibition of the enantioselective oxidative metabolism of metoprolol by verapamil in human liver microsomes

1 reference

12 December 2020

The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.

1 reference

12 December 2020

Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study

1 reference

12 December 2020

Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol

1 reference

12 December 2020

Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes

1 reference

12 December 2020

Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping

1 reference

12 December 2020

Polymorphic CYP2D6 mediates O -demethylation of the opioid analgesic tramadol

1 reference

12 December 2020

10.1007/S00228-006-0250-8

Identifiers

DOI

1 reference

15 August 2017

1 reference